Showing 1 - 7 results of 7 for search 'Béatrice Nawrocki Raby', query time: 0.03s Refine Results
  1. 1
    HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies

    HER2 Alterations in Non-Small Cell Lung Cancer: Biologico-Clinical Consequences and Interest in Therapeutic Strategies by Emma Loeffler, Julien Ancel, Véronique Dalstein, Gaëtan Deslée, Myriam Polette, Béatrice Nawrocki-Raby

    Published 2023-12-01
    Get full text
    Article
  2. 2
    Loss of the Metastasis Suppressor NME1, But Not of Its Highly Related Isoform NME2, Induces a Hybrid Epithelial–Mesenchymal State in Cancer Cells

    Loss of the Metastasis Suppressor NME1, But Not of Its Highly Related Isoform NME2, Induces a Hybrid Epithelial–Mesenchymal State in Cancer Cells by Anda Huna, Béatrice Nawrocki-Raby, Teresita Padilla-Benavides, Julie Gavard, Sylvie Coscoy, David Bernard, Mathieu Boissan

    Published 2021-04-01
    Get full text
    Article
  3. 3
    Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC

    Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC by Julien Ancel, Philippe Birembaut, Maxime Dewolf, Anne Durlach, Béatrice Nawrocki-Raby, Véronique Dalstein, Gonzague Delepine, Silvia Blacher, Gaëtan Deslée, Christine Gilles, Myriam Polette

    Published 2019-09-01
    Get full text
    Article
  4. 4
    Hypoxia in Lung Cancer Management: A Translational Approach

    Hypoxia in Lung Cancer Management: A Translational Approach by Julien Ancel, Jeanne-Marie Perotin, Maxime Dewolf, Claire Launois, Pauline Mulette, Béatrice Nawrocki-Raby, Véronique Dalstein, Christine Gilles, Gaëtan Deslée, Myriam Polette, Valérian Dormoy

    Published 2021-07-01
    Get full text
    Article
  5. 5
    Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors

    Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors by Julien Ancel, Julien Ancel, Valérian Dormoy, Béatrice Nawrocki Raby, Véronique Dalstein, Véronique Dalstein, Anne Durlach, Anne Durlach, Maxime Dewolf, Christine Gilles, Myriam Polette, Myriam Polette, Gaëtan Deslée, Gaëtan Deslée

    Published 2023-05-01
    Get full text
    Article
  6. 6
    S100A4 Is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma

    S100A4 Is a Biomarker of Tumorigenesis, EMT, Invasion, and Colonization of Host Organs in Experimental Malignant Mesothelioma by Joëlle S. Nader, Jordan Guillon, Coralie Petit, Alice Boissard, Florence Franconi, Stéphanie Blandin, Sylvia Lambot, Marc Grégoire, Véronique Verrièle, Béatrice Nawrocki-Raby, Philippe Birembaut, Olivier Coqueret, Catherine Guette, Daniel L. Pouliquen

    Published 2020-04-01
    Get full text
    Article
  7. 7
    Transcriptomic FHITlow/pHER2high signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer

    Transcriptomic FHITlow/pHER2high signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer by Audrey Brisebarre, Julien Ancel, Julien Ancel, Théophile Ponchel, Emma Loeffler, Adeline Germain, Véronique Dalstein, Véronique Dalstein, Valérian Dormoy, Anne Durlach, Anne Durlach, Gonzague Delepine, Gonzague Delepine, Gaëtan Deslée, Gaëtan Deslée, Myriam Polette, Myriam Polette, Béatrice Nawrocki-Raby

    Published 2022-12-01
    Get full text
    Article

Search Tools: